Momenta Pharmaceuticals (MNTA) 12.16 $MNTA
Teva Upgraded On Strength Of Copaxone MS Drug
at Investor's Business Daily - Fri Dec 12, 9:38AM CST
Sterne Agee upgraded Israeli drug giant Teva Pharmaceutical Industries (TEVA) to buy from neutral Friday, saying the outlook for its multiple-sclerosis drug Copaxone is better than most investors think. Teva issued 2015 guidance on Thursday morning,...
MYL: 53.32 (-1.39), TEVA: 55.92 (-0.92), MNTA: 12.16 (-0.04), NVS: 93.52 (-0.82)
Arthritis - Pipeline Review, H2 2014
M2 - Mon Dec 08, 3:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/42nbjz/arthritis) has announced the addition of the "Arthritis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arthritis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Arthritis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Arthritis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Eli Lilly and Company - GlaxoSmithKline - Nemucore Medical Innovations - Taisho Pharmaceutical - Sylentis - Astellas Pharma - Eisai - Bone Medical - Momenta Pharmaceuticals - Can-Fite BioPharma - Lexicon Pharmaceuticals - CSL Limited - WhanIn Pharmaceutical - Oscotec Inc. - Viron Therapeutics - PLx Pharma - Endocyte - Cardax Pharmaceuticals - Taiwan Liposome Company - NasVax - CalciMedica - Zyngenia - SelectX Pharmaceuticals - DoNatur - CellAct Pharma - Arcarios - Inbiopro Solutions - Sagene Pharmaceuticals - vida therapeutics - Dong-A Socio For more information visit http://www.researchandmarkets.com/research/42nbjz/arthritis
CANF: 3.49 (+0.03), LXRX: 0.85 (-0.05), LLY: 69.55 (-2.06), GSK: 42.42 (-0.93), MNTA: 12.16 (-0.04)
Insider Trading Alert - NUVA, MNTA And AKR Traded By Insiders
at The Street - Wed Dec 03, 9:15AM CST
Stocks with insider trader activity include NUVA, MNTA and AKR
AKR: 31.73 (-0.70), MNTA: 12.16 (-0.04), NUVA: 46.13 (-0.35)
Momenta's Necuparanib Gets Fast Track Status in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 02, 2:10PM CST
Momenta Pharmaceuticals, Inc.'s (MNTA) necuparanib (plus Abraxane and Gemzar) received fast track designation from the FDA for metastatic pancreatic cancer.
BIIB: 344.49 (+2.16), BAX: 71.77 (-1.34), ABBV: 65.27 (-1.76), MNTA: 12.16 (-0.04)
Insider Trading Alert - SUBK, PDCO And MNTA Traded By Insiders
at The Street - Tue Dec 02, 9:17AM CST
Stocks with insider trader activity include SUBK, PDCO and MNTA
PDCO: 47.44 (-0.72), SUBK: 20.67 (-1.02), MNTA: 12.16 (-0.04)
Momenta cancer drug candidate Fast Track'd
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 10:24AM CST
MNTA: 12.16 (-0.04)
Momenta Pharmaceuticals' Necuparanib Receives Fast Track Designation From the FDA for the Treatment of Patients With Metastatic Pancreatic Cancer
GlobeNewswire - Mon Dec 01, 7:15AM CST
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of necuparanib, the Company's novel oncology drug candidate, as a first-line treatment in combination with Abraxaneand gemcitabine in patients with metastatic pancreatic cancer. Momenta recently announced the successful completion of Part A of the Phase 1/2 study and has initiated the Part B (Phase 2 proof-of-concept) study.
MNTA: 12.16 (-0.04)
Momenta Pharmaceuticals Announces Acceptance of a Clinical Trial Application in Europe for M923, a Biosimilar Version of Humira(R)
GlobeNewswire - Mon Dec 01, 7:00AM CST
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the acceptance by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) of a Clinical Trial Application (CTA) to initiate a clinical trial for M923, a biosimilar version of Humira (adalimumab), in its collaboration with Baxter International's biopharmaceutical business. Acceptance of the CTA triggers two milestones under the Baxter collaboration with an aggregate payment of $12 million. Momenta expects to receive the payment in December 2014.
BAX: 71.77 (-1.34), MNTA: 12.16 (-0.04)
Insider Trading Alert - MNTA, DOC And DSCI Traded By Insiders
at The Street - Fri Nov 28, 9:15AM CST
Stocks with insider trader activity include MNTA, DOC and DSCI
DSCI: 8.60 (-0.20), DOC: 15.68 (-0.01), MNTA: 12.16 (-0.04)
Momenta Pharmaceuticals to Webcast Presentation at 2014 Deutsche Bank BioFEST
GlobeNewswire - Mon Nov 24, 3:30PM CST
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that its presentation at the 2014 Deutsche Bank BioFEST conference will be webcast on Monday, December 1 at 1:40 p.m. ET.
DB: 30.78 (-0.56), MNTA: 12.16 (-0.04)
Insider Trading Alert - MMLP, CTRL And MNTA Traded By Insiders
at The Street - Mon Nov 24, 9:15AM CST
Stocks with insider trader activity include MMLP, CTRL and MNTA
MMLP: 28.91 (-0.81), MNTA: 12.16 (-0.04), CTRL: 14.84 (-0.21)
Seres Health Appoints Biotechnology Finance Leader Eric Shaff as Chief Financial Officer
PR Newswire - Mon Nov 17, 8:00AM CST
Seres Health, Inc., a clinical-stage therapeutics company developing novel treatments for diseases related to the human microbiome, today announced that Eric Shaff has joined Seres as its Chief Financial Officer. Mr. Shaff will provide strategic financial guidance for Seres and manage the overall finances of the company.
MNTA: 12.16 (-0.04)
Momenta Pharmaceuticals' (MNTA) CEO Craig Wheeler Presents at Credit Suisse 2014 Healthcare Conference (Transcript)
SA Transcripts - at Seeking Alpha - Wed Nov 12, 6:39PM CST
MNTA: 12.16 (-0.04)
Momenta Pharmaceuticals to Webcast Presentation at Three Upcoming Investor Conferences
GlobeNewswire - Thu Nov 06, 7:42AM CST
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentation at three upcoming investor conferences.
MNTA: 12.16 (-0.04)
Momenta Pharmaceuticals' (MNTA) CEO Craig Wheeler on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 3:15PM CST
MNTA: 12.16 (-0.04)
Momenta Pharmaceuticals, Inc. Pushes Forward
Brian Orelli, The Motley Fool - Motley Fool - Wed Nov 05, 1:32PM CST
At this point, earnings calls for Momenta Pharmaceuticals are more an opportunity to update investors than to report revenue and earnings. Because, let's face it... sales of Momenta's and Novartis ' enoxaparin, a generic version of Sanofi 's ...
BAX: 71.77 (-1.34), TEVA: 55.92 (-0.92), ABBV: 65.27 (-1.76), SNY: 45.16 (-1.05), MNTA: 12.16 (-0.04), NVS: 93.52 (-0.82)
Momenta updates guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 9:03AM CST
MNTA: 12.16 (-0.04)
Momenta Pharmaceuticals (MNTA) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 05, 8:55AM CST
MNTA: 12.16 (-0.04)
Momenta misses 3Q profit forecasts
Automated Insights - Wed Nov 05, 8:09AM CST
CAMBRIDGE, Mass. (AP) _ Momenta Pharmaceuticals Inc. (MNTA) on Wednesday reported a third-quarter loss of $29.1 million.
MNTA: 12.16 (-0.04)
Momenta Pharmaceuticals misses by $0.13, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 7:04AM CST
MNTA: 12.16 (-0.04)
Teva Upgraded On Strength Of Copaxone MS Drug
at Investor's Business Daily - Fri Dec 12, 9:38AM CST
Sterne Agee upgraded Israeli drug giant Teva Pharmaceutical Industries (TEVA) to buy from neutral Friday, saying the outlook for its multiple-sclerosis drug Copaxone is better than most investors think. Teva issued 2015 guidance on Thursday morning,...
MYL: 53.32 (-1.39), TEVA: 55.92 (-0.92), MNTA: 12.16 (-0.04), NVS: 93.52 (-0.82)
Arthritis - Pipeline Review, H2 2014
M2 - Mon Dec 08, 3:23AM CST
Research and Markets (http://www.researchandmarkets.com/research/42nbjz/arthritis) has announced the addition of the "Arthritis - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Arthritis, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Arthritis and special features on late-stage and discontinued projects. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies - Identify and understand important and diverse types of therapeutics under development for Arthritis - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Arthritis pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline Companies Mentioned: - Eli Lilly and Company - GlaxoSmithKline - Nemucore Medical Innovations - Taisho Pharmaceutical - Sylentis - Astellas Pharma - Eisai - Bone Medical - Momenta Pharmaceuticals - Can-Fite BioPharma - Lexicon Pharmaceuticals - CSL Limited - WhanIn Pharmaceutical - Oscotec Inc. - Viron Therapeutics - PLx Pharma - Endocyte - Cardax Pharmaceuticals - Taiwan Liposome Company - NasVax - CalciMedica - Zyngenia - SelectX Pharmaceuticals - DoNatur - CellAct Pharma - Arcarios - Inbiopro Solutions - Sagene Pharmaceuticals - vida therapeutics - Dong-A Socio For more information visit http://www.researchandmarkets.com/research/42nbjz/arthritis
CANF: 3.49 (+0.03), LXRX: 0.85 (-0.05), LLY: 69.55 (-2.06), GSK: 42.42 (-0.93), MNTA: 12.16 (-0.04)
Insider Trading Alert - NUVA, MNTA And AKR Traded By Insiders
at The Street - Wed Dec 03, 9:15AM CST
Stocks with insider trader activity include NUVA, MNTA and AKR
AKR: 31.73 (-0.70), MNTA: 12.16 (-0.04), NUVA: 46.13 (-0.35)
Momenta's Necuparanib Gets Fast Track Status in the U.S. - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Dec 02, 2:10PM CST
Momenta Pharmaceuticals, Inc.'s (MNTA) necuparanib (plus Abraxane and Gemzar) received fast track designation from the FDA for metastatic pancreatic cancer.
BIIB: 344.49 (+2.16), BAX: 71.77 (-1.34), ABBV: 65.27 (-1.76), MNTA: 12.16 (-0.04)
Insider Trading Alert - SUBK, PDCO And MNTA Traded By Insiders
at The Street - Tue Dec 02, 9:17AM CST
Stocks with insider trader activity include SUBK, PDCO and MNTA
PDCO: 47.44 (-0.72), SUBK: 20.67 (-1.02), MNTA: 12.16 (-0.04)
Momenta cancer drug candidate Fast Track'd
Seeking Alpha - at Seeking Alpha - Mon Dec 01, 10:24AM CST
MNTA: 12.16 (-0.04)
Momenta Pharmaceuticals' Necuparanib Receives Fast Track Designation From the FDA for the Treatment of Patients With Metastatic Pancreatic Cancer
GlobeNewswire - Mon Dec 01, 7:15AM CST
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to the investigation of necuparanib, the Company's novel oncology drug candidate, as a first-line treatment in combination with Abraxaneand gemcitabine in patients with metastatic pancreatic cancer. Momenta recently announced the successful completion of Part A of the Phase 1/2 study and has initiated the Part B (Phase 2 proof-of-concept) study.
MNTA: 12.16 (-0.04)
Momenta Pharmaceuticals Announces Acceptance of a Clinical Trial Application in Europe for M923, a Biosimilar Version of Humira(R)
GlobeNewswire - Mon Dec 01, 7:00AM CST
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the acceptance by the UK Medicines and Healthcare Products Regulatory Agency (MHRA) of a Clinical Trial Application (CTA) to initiate a clinical trial for M923, a biosimilar version of Humira (adalimumab), in its collaboration with Baxter International's biopharmaceutical business. Acceptance of the CTA triggers two milestones under the Baxter collaboration with an aggregate payment of $12 million. Momenta expects to receive the payment in December 2014.
BAX: 71.77 (-1.34), MNTA: 12.16 (-0.04)
Insider Trading Alert - MNTA, DOC And DSCI Traded By Insiders
at The Street - Fri Nov 28, 9:15AM CST
Stocks with insider trader activity include MNTA, DOC and DSCI
DSCI: 8.60 (-0.20), DOC: 15.68 (-0.01), MNTA: 12.16 (-0.04)
Momenta Pharmaceuticals to Webcast Presentation at 2014 Deutsche Bank BioFEST
GlobeNewswire - Mon Nov 24, 3:30PM CST
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that its presentation at the 2014 Deutsche Bank BioFEST conference will be webcast on Monday, December 1 at 1:40 p.m. ET.
DB: 30.78 (-0.56), MNTA: 12.16 (-0.04)
Insider Trading Alert - MMLP, CTRL And MNTA Traded By Insiders
at The Street - Mon Nov 24, 9:15AM CST
Stocks with insider trader activity include MMLP, CTRL and MNTA
MMLP: 28.91 (-0.81), MNTA: 12.16 (-0.04), CTRL: 14.84 (-0.21)
Seres Health Appoints Biotechnology Finance Leader Eric Shaff as Chief Financial Officer
PR Newswire - Mon Nov 17, 8:00AM CST
Seres Health, Inc., a clinical-stage therapeutics company developing novel treatments for diseases related to the human microbiome, today announced that Eric Shaff has joined Seres as its Chief Financial Officer. Mr. Shaff will provide strategic financial guidance for Seres and manage the overall finances of the company.
MNTA: 12.16 (-0.04)
Momenta Pharmaceuticals' (MNTA) CEO Craig Wheeler Presents at Credit Suisse 2014 Healthcare Conference (Transcript)
SA Transcripts - at Seeking Alpha - Wed Nov 12, 6:39PM CST
MNTA: 12.16 (-0.04)
Momenta Pharmaceuticals to Webcast Presentation at Three Upcoming Investor Conferences
GlobeNewswire - Thu Nov 06, 7:42AM CST
Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced that it will webcast its presentation at three upcoming investor conferences.
MNTA: 12.16 (-0.04)
Momenta Pharmaceuticals' (MNTA) CEO Craig Wheeler on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Wed Nov 05, 3:15PM CST
MNTA: 12.16 (-0.04)
Momenta Pharmaceuticals, Inc. Pushes Forward
Brian Orelli, The Motley Fool - Motley Fool - Wed Nov 05, 1:32PM CST
At this point, earnings calls for Momenta Pharmaceuticals are more an opportunity to update investors than to report revenue and earnings. Because, let's face it... sales of Momenta's and Novartis ' enoxaparin, a generic version of Sanofi 's ...
BAX: 71.77 (-1.34), TEVA: 55.92 (-0.92), ABBV: 65.27 (-1.76), SNY: 45.16 (-1.05), MNTA: 12.16 (-0.04), NVS: 93.52 (-0.82)
Momenta updates guidance after Q3 results
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 9:03AM CST
MNTA: 12.16 (-0.04)
Momenta Pharmaceuticals (MNTA) Q3 2014 Results - Earnings Call Webcast
SA Transcripts - at Seeking Alpha - Wed Nov 05, 8:55AM CST
MNTA: 12.16 (-0.04)
Momenta misses 3Q profit forecasts
Automated Insights - Wed Nov 05, 8:09AM CST
CAMBRIDGE, Mass. (AP) _ Momenta Pharmaceuticals Inc. (MNTA) on Wednesday reported a third-quarter loss of $29.1 million.
MNTA: 12.16 (-0.04)
Momenta Pharmaceuticals misses by $0.13, misses on revenue
Seeking Alpha - at Seeking Alpha - Wed Nov 05, 7:04AM CST
MNTA: 12.16 (-0.04)
